Trial Profile
Phase II study of neoadjuvant Letrozole combined with low dose metronomic Cyclophosphamide for postmenopausal women with Endocrine-responsive Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2019
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Letrozole (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- 24 Aug 2015 Status changed from active,no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 22 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 25 Aug 2008 New trial record.